It appeared to provoke good immune response in Chinese study, but larger trials are needed
WEDNESDAY, March 25, 2015 (HealthDay News) -- An
experimental Ebola vaccine shows promise in an early clinical trial, but
requires much more testing, researchers report.
The trial included 120 healthy adults in China who received either a
low or high dose of the vaccine, or a placebo. Twenty-eight days later,
38 of 40 people in the low-dose group and all 40 of those in the
high-dose group showed an immune response to the vaccine.
No serious side effects occurred among the participants who received the vaccine.
While the results suggest the vaccine is effective and safe, more
long-term testing is needed to determine whether it can actually protect
people against Ebola, according to the authors of the study published
March 25 in The Lancet.
The vaccine is based on the strain of Ebola that has been circulating
in the West African outbreak. The researchers note that, until now, all
tested Ebola vaccines have been based on the Ebola strain from the 1976
outbreak in Zaire.
The vaccine was developed by the Beijing Institute of Biotechnology
and Tianjin CanSino Biotechnology in China. Both helped fund the study,
along with China National Science and Technology.
"On the basis of our findings, we believe that the Ebola vaccine we
assessed has some potential, and a significant advantage of this type of
vaccine is that [it is] stable and much easier to store or transport in
tropical areas with inadequate cold-chain capacity, such as Africa,"
research team leader Fengcai Zhu, from the Jiangsu provincial center for
disease prevention and control in China, said in a journal news
release.
"However, whether this candidate vaccine could become a final vaccine
for widespread use against Ebola outbreaks is still uncertain," Zhu
added. "Furthermore, these results only assess immune response up to 28
days, so we plan to assess the persistence of the specific immune
response by following up the vaccine recipients of this study."
Still, two experts said the development of the vaccine is a testament to how scientists can effectively respond in a crisis.
This vaccine, "is an example of how quickly existing vaccine
platforms can be modified to incorporate a new virus strain, and moved,
with minimum testing in animals, into trials in humans during a crisis
situation," Andrea Marzi, of the U.S. National Institute of Allergy and
Infectious Diseases, and Darryl Falzarano, of the University of
Saskatchewan in Canada, wrote in an accompanying commentary.
"However...ultimately, the effectiveness of all these vaccines will
only become clear when they proceed to phase 2 efficacy trials in
outbreak regions," they added.
The West African Ebola outbreak, while ebbing, is not yet over.
According to the U.S. Centers for Disease Control and Prevention, almost
25,000 probable or confirmed cases have been detected in Guinea,
Liberia and Sierra Leone, including more than 10,000 deaths.
SOURCE: The Lancet, news release, March 25, 2015
REFERENCE